NCT06790121 - A Study to Investigate the Efficacy and Safety of Subcutaneous Lunsekimig (SAR443765) Compared With Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis | Biotech Hunter

Enrollment

150

Participants

Timeline

Start Date

February 3, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

April 13, 2026

Conditions

Dermatitis Atopic

Interventions

DRUG

Lunsekimig

Pharmaceutical form: Solution for injection in vial Route of administration: Subcutaneous injection

DRUG

Placebo

Pharmaceutical form: Solution for injection in vial Route of administration: Subcutaneous injection

Trial Locations (16)

33134

Driven Research LLC-Site Number: 8400020, Coral Gables

33486

Skin Care Research-Site Number: 8400013, Boca Raton

46168

Indiana Clinical Trials Center, P.C.-Site Number: 8400018, Plainfield

47150

Southern Indiana Clinical Trials-Site Number: 8400024, New Albany

57702

Health Concepts-Site Number: 8400025, Rapid City

58103

Red River Research Partners-Site Number: 8400008, Fargo

64506

Medisearch LLC-Site Number: 8400017, Saint Joseph

70433

Clinical Trials Management LLC-Site Number: 8400010, Covington

78759

DermResearch-Site Number: 8400014, Austin

89509

Skin Cancer and Dermatology Institute-Site Number: 8400011, Reno

91320

Clinical Trials Research Institute-Site Number: 8400003, Thousand Oaks

91436

T. Joseph Raoof MD Inc-Site Number: 8400004, Encino

070-8610

Investigational Site Number: 3920005, Asahikawa-shi

177-0041

Investigational Site Number: 3920006, Nerima-ku

190-0023

Investigational Site Number: 3920008, Tachikawa-shi

221-0825

Investigational Site Number: 3920007, Yokohama